Vaishali Pharma Ltd
Incorporated in 1989, Vaishali Pharma Ltd
does marketing of pharmaceutical products including active pharmaceutical ingredients[1]
- Market Cap ₹ 101 Cr.
- Current Price ₹ 7.76
- High / Low ₹ 13.1 / 4.75
- Stock P/E 24.3
- Book Value ₹ 5.30
- Dividend Yield 0.00 %
- ROCE %
- ROE 6.02 %
- Face Value ₹ 2.00
Pros
Cons
- Promoter holding is low: 31.6%
- Earnings include an other income of Rs.3.84 Cr.
- Company has high debtors of 170 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2026 | |
|---|---|
| 109 | |
| 105 | |
| Operating Profit | 4 |
| OPM % | 4% |
| 4 | |
| Interest | 2 |
| Depreciation | 1 |
| Profit before tax | 5 |
| Tax % | 25% |
| 4 | |
| EPS in Rs | 0.32 |
| Dividend Payout % | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 14% |
| 3 Years: | -18% |
| 1 Year: | -37% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 6% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2026 | |
|---|---|
| Equity Capital | 26 |
| Reserves | 43 |
| 19 | |
| 35 | |
| Total Liabilities | 123 |
| 2 | |
| CWIP | 0 |
| Investments | 6 |
| 116 | |
| Total Assets | 123 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2026 | |
|---|---|
| Net Cash Flow | |
| Free Cash Flow | |
| CFO/OP |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2026 | |
|---|---|
| Debtor Days | 170 |
| Inventory Days | 13 |
| Days Payable | 81 |
| Cash Conversion Cycle | 102 |
| Working Capital Days | 212 |
| ROCE % |
Insights
In beta| Mar 2017 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| Countries Exported To count |
|
||||||
| Export Revenue (FOB) Rs. Crores |
|||||||
| Formulation Brands Registered count |
|||||||
| Product Registrations Approved count |
|||||||
| Products in Portfolio count |
|||||||
| Customers count |
|||||||
| Product Registrations Applied count |
|||||||
| Distributors (Export) count |
|||||||
Extracted by Screener AI
Documents
Announcements
-
Certificate under SEBI (Depositories and Participants) Regulations, 2018
15 July 2026 - Submitted Regulation 74(5) certificate for quarter ended 30 June 2026; no rematerialisation requests received.
-
Outcome of Board Meeting
9 July 2026 - Vaishali Pharma Limited has informed regarding Outcome of Board Meeting held on July 08, 2026.
-
Shareholders meeting
4 July 2026 - Shareholders approved postal ballot resolutions on 4 July 2026 reappointing directors and increasing CFO remuneration.
-
Allotment of Securities
3 July 2026 - Allotted 45,37,865 shares at Rs20 each to Kesar Pharma, totaling Rs9.08 crore for 26.95% stake.
-
General Updates
3 July 2026 - Allotted 45.38 lakh shares at Rs.20 each to acquire 26.95% stake in Kesar Pharma.
Annual reports
Concalls
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT
-
Aug 2020TranscriptAI SummaryPPT
-
May 2020TranscriptAI SummaryPPT
Business Overview:[1]
VPL is certified by ISO 9001:2008 and provides 1500+ products and 250+ Brands including APIs, Formulations, Surgical, Herbals, Veterinary, Nutraceutical, Oncology, and other healthcare products in 35+ locations